This study will evaluate the efficacy and safety of Faslodex as secondary-line treatment compared with Arimidex in oestrogen receptor positive postmenopausal advanced breast cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
234
250 mg intramuscular injection
1 mg tablet
Research Site
Beijing, China
Research Site
Dalian, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Time to Disease Progression (TTP)
Objective Response Rate (ORR)
Clinical Benefit Rate (CBR)
Time to Treatment Failure (TTF)
Safety & Tolerability.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Hankou, China
Research Site
Hefei, China
Research Site
Huangzhou, China
Research Site
Jinan, China
Research Site
Nanjing, China
Research Site
Shanghai, China
...and 2 more locations